31
Participants
Start Date
October 28, 2014
Primary Completion Date
May 28, 2020
Study Completion Date
May 28, 2020
LUM001 (Maralixibat)
LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
Placebo
Placebo will be administered orally once daily during randomized withdrawal period
Hospital Universitario La Paz- Hospital Materno Infantil, Madrid
Children's Hospital Westmead, Westmead
The Royal Children's Hospital Melbourne, Parkville
Hopital Femme Mere Enfant De Lyon, Bron
Hopital Necker-Enfants Malades, Paris
Hopital Kremlin Bicetre, Paris
Cliniques Universitaires Saint-Luc, Brussels
The Children's Memorial Health Institute, Warsaw
Paediatric Liver Center, Kings College Hospital, London
Lead Sponsor
Mirum Pharmaceuticals, Inc.
INDUSTRY